Bringing Clinical Trials to Life

Pediatrics

Pediatric trials run the gamut of indications in drug development, but they all have primary things in common – working with children and their families requires specialized expertise and deep knowledge of regulatory requirements….
More...

Dermatology

Together, Cu-Tech and Synteract create the leading dermatology CRO, with global capabilities and unparalleled access to sites and patients. Our focus on novel and required dermatology drugs provides dedicated research services unmatched in the market.
More...

Oncology

Like our clients, we are committed to the quest to cure cancer. But cancer is not just a single disease. It takes deep trial knowledge to know how to address its many forms. Learn how Synteract has stayed ahead of the trends leading towards new treatments…
More...

Neuro Degenerative

Neuro degenerative disorders are some of the most confounding and complex to affect people. Our specialized experience in these trials aids you in developing treatments that improve functioning and help the lives of both patients and caregivers…
More...

Rare & Orphan Diseases

Rare and orphan diseases have unique characteristics, not the least of which is finding the right population for your trials. We know the investigators and study sites that can help to address your recruitment goals, among other challenges…
More...

2/12/2019 - 2/13/2019 : Outsourcing in Clinical Trials West Coast Booth # 21 More...

11/15/2018: Synteract has acquired KinderPharm, a specialty pediatric CRO, focused on advancing pediatric drug development across all phases of clinical research. More ...

11/20/2018: 5 Reasons to Work with Synteract For Your Pediatric Clinical Trial - Whether you are looking for small scale support, assistance with a specific service, or complete study design and management, Synteract draws on extensive, end-to-end experience in helping clients efficiently navigate the complexities of pediatric trials and regulatory environments.

Synteract Blog 

12/16/2018: “Many rare diseases are devastating to patients, and not much is known about them. Advocacy groups are key in keeping the patient at the forefront of research,” said Elisabeth Schrader, Synteract’s Executive Director of Pediatric, Rare and Orphan Program Strategy and Delivery. Elisabeth spoke with http://ow.ly/x1b350jVzBg and discussed the key challenges facing rare and orphan disease trials: http://ow.ly/9Pbd50jVzBf

Synteract on LinkedIn

12/14/2018: We have years of experience bringing #pediatric trials to life. See why working with us makes the process seamless… https://t.co/axvK3gdsJG

Synteract Twitter Feed
x

Contact Synteract

Tell us how to stay in touch with you:

*Required